<DOC>
	<DOCNO>NCT02703740</DOCNO>
	<brief_summary>This study evaluate injection hyaluronic acid dermal filler lidocaine 0.3 % treatment nasolabial fold ( NLF ) . Each patient receive 1 concentration NLF ( 20 mg/mL ) concentration NLF ( 24 mg/mL ) .</brief_summary>
	<brief_title>Long Term Safety Efficacy Assessment Hyaluronic Acid Dermal Filler With Treatment Nasolabial Folds</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Is least 19 year age . Has Fitzpatrick Skin Type IV , V , VI . Has WSRS score &gt; = 3 NLF Understands accept obligation receive procedure treatments nasolabial fold 6 month Has keloid formation , hypertrophic scar dyschromic scaring . Has hypersensitivity hyaluronic acid , Chlorhexidine lidocaine local anaesthetic drug Has know bleed disorder receive drug therapy could increase risk bleed . Has nasolabial fold severe correct one treatment session . Has receive dermal filler injection , graft surgery either nasolabial fold last year . Is pregnant , lactating , use acceptable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>